

Farletuzumab ecteribulin

Chemical Properties

CAS No. : 2407465-18-1

Formula:

Molecular Weight:

Store at low temperature

Storage: Store at -20°C

Actual storage temperature shall be subject to the COA.

Biological Description

Description	Farletuzumab ecteribulin is an antibody-drug conjugate (ADC) consisting of the humanized antibody farletuzumab, which targets the folate receptor alpha (FRA), with an antibody-to-drug ratio of 4.0. In vitro, farletuzumab ecteribulin exhibits cytotoxic and antitumor activity against FRA-positive cells.
Targets(IC50)	Antibody-Drug Conjugates (ADCs)
In vitro	Methods: FRA-positive tumor cells were treated with farletuzumab ecteribulin (5.1 pM-10 µM) for 5 consecutive days. Results: Farletuzumab ecteribulin showed potent cytotoxicity against FRA-positive cells, with an IC ₅₀ of 1 nM in IGROV-1 cells, 74 nM in NCI-H2110 cells, and 2.3 µM in A431-A3 cells [1].
In vivo	Farletuzumab ecteribulin (MORAb-202; intravenous administration; a single injection of 1, 5 mg/kg on Day 0; or injections of 5 mg/kg every 11 days for a total of 2 doses; 60 days) demonstrated significant antitumor activity at one or two doses of 5 mg/kg [1]. With a dosage of 2 mg/kg intravenously, the half-life (T _{1/2}) of farletuzumab ecteribulin on Day 1 was 192 hours in male and 162 hours in female cynomolgus monkeys, with corresponding AUC (0-t) values of 7160 and 6300 µg·h/mL, respectively [1].

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286

E_mail:info@targetmol.com

Address:34 Washington Street,Wellesley Hills,MA 02481